Orchid Pharma share price rose 2 percent in the opening trade on February 20 following the company received seven minor observations for API manufacturing facility in Alathur, Tamil Nadu.
At 09:21am, Orchid Pharma was quoting at Rs 852.00, up Rs 17.35, or 2.08 percent on the BSE.
".... announced the successful completion of a surprise US Food and Drug Administration (USFDA) inspection at its Active Pharmaceutical Ingredient (API) manufacturing facility in Alathur, Tamil Nadu."
"The inspection, which commenced on 10 February 2025 and concluded on 18 February 2025, resulted in seven minor observations, none of which pertain to the data integrity of the facility," it added
The Alathur facility specializes in the production of Cephalosporin antibiotics, a critical class of life-saving drugs.
Additionally, the Alathur API facility has also secured the renewal of its EU Good Manufacturing Practice (GMP) certificate following a successful inspection. This further validates the facility’s compliance with European regulatory requirements and its capability to serve global markets.
Catch all the market action on our live blog
The company had posted 21.7 percent fall in its December quarter (Q3FY25) net profit at Rs 23.91 crore against Rs 30.55 crore in December 2023.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
